- Initial clinical trial and pharmacokinetics of Thymitaq (AG337) by 10-day continuous infusion in patients with advanced solid tumors. Creaven, P.J., Pendyala, L., Meropol, N.J., Clendeninn, N.J., Wu, E.Y., Loewen, G.M., Proefrock, A., Johnston, A., Dixon, M. Cancer Chemother. Pharmacol. (1998)









